Moderna to Present Phase 1/2 Interim Data on mRNA-3927
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacementTo date, mRNA-3927 has been generally well-tolerated at the doses administered, with...
-
-
Morgan Stanley maintains Moderna at Equalweight, PT $153.00
A Morgan Stanley analyst maintained Moderna (NASDAQ: MRNA) at Equalweight and a price target of $153.00 from a prior price target of %currency%%price%. Prior to this rating, Moderna had 11...
-
Moderna Files Mixed Shelf
Moderna (MRNA) has filed mixed shelf of:Common StockPreferred StockDebt SecuritiesWarrantsUnits
-
Moderna Q1 earnings, revenue surprisingly tops consensus estimates
Moderna (NASDAQ:MRNA) shares opened higher Thursday on the back of its surprising earnings and revenue beat. The drugmaker had been expected to post a $1.75 loss in the quarter, however,...
-
PacWest, First Horizon, Paramount fall premarket; Shopify, Moderna rise
Investing.com -- Stocks in focus in premarket trade on Thursday, May 4th. Please refresh for updates. PacWest Bancorp (NASDAQ:PACW) stock fell 40% after the regional lender confirmed...
-
Dow futures fall 90 pts; banking turmoil continues after Fed hike
Investing.com -- U.S. stocks are seen opening in a subdued fashion Thursday as investors digest the Federal Reserve’s latest policy move as well as more turmoil in the banking...
-
Moderna earnings beat by $1.94, revenue topped estimates
Investing.com - Moderna (NASDAQ: MRNA) reported first quarter EPS of $0.19, $1.94 better than the analyst estimate of $-1.75. Revenue for the quarter came in at $1.9B versus the consensus...
-
Dow futures trade lower, PacWest tanks 55.6% on sale reports
Investing.com - U.S. stock futures were trading lower during Wednesday's evening deals, after major benchmark indices extended declines during the regular session, with Federal Reserve...
-
Moderna Announces Phase 1/2 Data on mRNA-3927
After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the...
-
Moderna Establishes Enterprise Solutions Hub and Commercial Operations in The Philippines
The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna (NASDAQ:MRNA)'s Enterprise Solutions Hubs in Warsaw, Poland, and Atlanta,...
-
First Republic, Fed meeting, Apple earnings - what's moving markets
Investing.com -- First Republic Bank has been taken over by Californian authorities with JPMorgan Chase assuming its deposits, at the start of a week that includes a Federal Reserve meeting,...
-
Top 5 things to watch in markets in the week ahead
Investing.com -- Wednesday's Federal Reserve decision is set to be the highlight of the week, with the central bank expected to announce another quarter point rate hike. A barrage of...
-
Guggenheim new coverage Moderna Neutral, PT $No data
A Guggenheim analyst initiated new coverage Moderna (NASDAQ: MRNA) Neutral rating and a price target of $No data. Prior to this rating, Moderna had 11 buy ratings, 8 hold ratings, and 1...
-
Stock market today: Dow ends down on Tesla drag, economic jitters
By Yasin Ebrahim Investing.com -- The Dow pared some losses Thursday, but ended lower as Tesla led a slew of mostly disappointing quarter results just as economic data stoked further worries...
-
S&P 500 slides on Tesla slump, economic jitters
By Yasin Ebrahim Investing.com -- The S&P 500 slipped Wednesday as investor sentiment was soured by disappointing quarterly results including from Tesla and economic data pointing to a...
-
Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
Moderna invests in developing quantum computing skills and exploring the use of quantum computing in developing future mRNA medicinesModerna, Inc. (Nasdaq: MRNA), a biotechnology company...
-
FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines
Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna (NASDAQ:MRNA) and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify...
-
Moderna, Xpeng and Uber rise premarket; State Street falls
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, April 17th. Please refresh for updates. Merck (NS:PROR) (NYSE:MRK) stock fell 0.1% after the drugs giant...
-
Moderna stock gains on trial results for its melanoma vaccine with Merck; data seen as 'stunning'
By Senad Karaahmetovic Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) announced the results of a closely-watched Phase 2b personalized cancer vaccine (PCV) trial for melanoma. The results...
-
Moderna's mRNA-4157 in combo with Merck's KEYTRUDA reduced the risk of recurrence or death by 44% in melanoma patients
Moderna, Inc. (Nasdaq: MRNA) and Merck (MRK) announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an...
-
BofA expresses concerns about Moderna guidance, which 'may be a high bar'
By Sam Boughedda BofA was left with more questions than answers following Moderna 's (NASDAQ:MRNA) Vaccines Day, BofA analysts told investors in a note Wednesday. The analysts, who have...
-
BofA Securities maintains Moderna at Neutral
A BofA Securities analyst maintained Moderna (NASDAQ: MRNA) at Neutral and a price target of $200.00. Prior to this rating, Moderna had 11 buy ratings, 8 hold ratings, and 1 sell...
-
Stock market today: Dow closes higher as cyclicals advance ahead of inflation data
By Yasin Ebrahim Investing.com -- The Dow closed higher Tuesday, driven by cyclical corners of the market including energy and financial stocks, though investor sentiment remained cautious...
-
Midday movers: CarMax, Moderna, Coinbase Global
By Liz Moyer Investing.com -- Stocks are mixed on Tuesday as investors weigh the odds of the Federal Reserve raising interest rates again in May. Here are the market movers for April 11. ...
-
S&P 500 advances on rising energy stocks; Inflation data eyed
By Yasin Ebrahim Investing.com -- The S&P 500 climbed Tuesday, underpinned by a jump in energy stocks, though sentiment remains cautious ahead of the fresh inflation data due Wednesday that...
-
CarMax, Getty Images and Coinbase rise premarket; Moderna falls
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, April 11th. Please refresh for updates. CarMax (NYSE:KMX) stock rose 7.3% after the used car retailer posted...
-
Moderna stock drops 5% as its flu vaccine fails to meet 'early success' criteria
By Senad Karaahmetovic Shares of Moderna (NASDAQ:MRNA) are trading about 5% lower in pre-market Tuesday after the biotech company suffered a setback on its first flu vaccine. Moderna...
-
Moderna Announces Clinical and Program Updates at 4th Vaccines Day
Next-generation, refrigerator-stable COVID-19 vaccine candidate, mRNA-1283, has dosed first participant in its Phase 3 trialCompany expects to file for approval of its investigational RSV...
-
JPMorgan maintains Moderna at Neutral
A JPMorgan analyst maintained Moderna (NASDAQ: MRNA) at Neutral and a price target of $145.00 from a prior price target of %currency%%price%. Prior to this rating, Moderna had 11 buy...
-
Moderna and Merck Report MRNA-4157/V940 in Combination With Keytruda Received Prime Scheme Designation in EU
oderna, Inc. (MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (MRK), known as MSD outside of the United States and Canada, today announced...
-
Moderna Finalizes Agreement with the Government of Kenya to Establish an mRNA Manufacturing Facility
Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna (NASDAQ:MRNA)'s global public health...
-
Moderna and Generation Bio Announce Pact to Develop Non-Viral Genetic Medicines
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating...
-
Moderna to Price Its Covid-19 Vaccine at $130 a Dose on the Commercial Market, Company President Says -- WSJ
Moderna (NASDAQ:MRNA) to Price Its Covid-19 Vaccine at $130 a Dose on the Commercial Market, Company President Says -- WSJ$130-a-Dose Price Reflects Value of Moderna's Vaccine in...
-
Moderna stock gains as TD Cowen upgrades on favorable catalyst path
By Senad Karaahmetovic TD Cowen analysts upgraded Moderna (NASDAQ:MRNA) shares to Outperform from Market Perform with the price target raised to $180 per share from the prior $150. The...
-
Moderna announces U.S. expansion and 2023
By Michael Elkins Moderna, Inc., (NASDAQ:MRNA) announced Friday that the biotechnology company is expanding its U.S. presence. The company plans to establish a corporate presence on the...
-
Moderna plans to hire approximately 2,000 new employees in 2023
oderna, Inc., (MRNA) announced that it is expanding its U.S. presence and establishing a corporate presence on the West Coast with new offices in South San Francisco, California and Seattle,...
-
Today's most important initiations
By Davit Kirakosyan Scotiabank initiated coverage on Array Technologies (NASDAQ:ARRY) with a Sector Outperform rating and a price target of $26.00. While noting that near-term uncertainties...
-
Moderna started at Outperform as 'COVID Cliff' near-term impact well appreciated
By Sam Boughedda RBC Capital Markets initiated coverage of Moderna (NASDAQ:MRNA) with an Outperform rating and a $200 per share price target on Thursday. RBC analysts told investors in...
-
UBS: Moderna's clinical-stage vaccines could drive post-COVID revenues
By Scott Kanowsky Investing.com -- Vaccines in clinical stage trials may help Moderna (NASDAQ:MRNA) bolster revenue as demand for COVID-19 jabs eases, according to analysts at...
-
Moderna changes point to an 'extended period of underperformance' - SVB Securities
By Sam Boughedda Moderna (NASDAQ:MRNA) was cut to Underperform from Market Perform by SVB Securities analysts on Friday. They also lowered the firm's price target on the stock to $93...
-
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.33%
Investing.com – U.S. stocks were higher after the close on Thursday, as gains in the Oil&Gas, Technology and Industrials sectors led shares higher. At the close in NYSE, the Dow Jones...
-
Stock market today: Dow fights back to close higher as Nvidia shines
By Yasin Ebrahim Investing.com -- The Dow closed higher Thursday, but investors had to contend with wild swings in markets, weighing up ongoing fears about Federal Reserve rate hikes and an...
-
S&P 500 advances in choppy trade as Nvidia rally bolsters tech
By Yasin Ebrahim Investing.com -- The S&P 500 rose Thursday, but trading remained choppy as investors weigh fears about Federal Reserve rate hikes and an Nvidia-led jump in tech. The S&P 500...
-
U.S. stocks are rising after Nvidia's upbeat outlook
By Liz Moyer Investing.com -- U.S. stocks are rising after a strong sales outlook from chipmaker Nvidia. At 10:02 ET (15:02 GMT), the Dow Jones Industrial Average was up 162 points or 0.5%,...
-
Moderna falls as waning demand for COVID-19 vaccines hit sales, profit
By Geoffrey Smith Investing.com -- Moderna (NASDAQ:MRNA) stock fell in premarket trading after the company reported a shop drop in profit at the end of last year, as demand for its COVID-19...
-
Moderna Q4 Revenue Tops Consensus
Moderna (NASDAQ:MRNA) reported Q4 EPS of $3.61, $1.09 worse than the analyst estimate of $4.70. Revenue for the quarter came in at $5.1 billion versus the consensus estimate of $5.05...
-
Moderna earnings missed by $1.09, revenue topped estimates
Investing.com - Moderna (NASDAQ: MRNA) reported fourth quarter EPS of $3.61, $1.09 worse than the analyst estimate of $4.70. Revenue for the quarter came in at $5.1B versus the consensus...
-
Moderna . Merck Announce mRNA-4157/V940 in Combination With KEYTRUDA was Granted Breakthrough Therapy Designation by FDA for Adjuvant Treatment of Patients With High-Risk Mela
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial Moderna , Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and...
-
GDP reading, Booking Holdings, Moderna: 3 things to watch
By Liz Moyer Investing.com -- Stocks wobbled on Wednesday as the minutes of the Fed's most recent meeting revealed that most policymakers wanted to slow the pace of interest rate hikes so...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
